Literature DB >> 29027080

Different expression systems resulted in varied binding properties of anti-paclitaxel single-chain variable fragment antibody clone 1C2.

Gorawit Yusakul1,2, Seiichi Sakamoto1, Poomraphie Nuntawong3, Hiroyuki Tanaka4, Satoshi Morimoto1.   

Abstract

The binding properties of recombinant antibody fragments, such as affinity and specificity, determine their usefulness for therapeutic and analytical applications. Anti-paclitaxel single-chain variable fragment clone 1C2 (anti-PT scFv1C2) was expressed using Escherichia coli cell and Bombyx mori larvae expression systems. The binding characteristics of the scFvs were evaluated using indirect competitive ELISA. The linear range of binding between anti-PT scFv1C2 and paclitaxel was significantly different between the anti-PT scFv1C2s derived from E. coli (1.056-5.700 μg/ml) and B. mori (7.813-1000 ng/ml), which indicated that different expression systems resulted in different sensitivities for paclitaxel determination. In addition, the binding specificity of anti-PT scFv1C2 varied between expression systems. This finding implied that the expression system significantly affects the binding properties of recombinant antibodies, especially antibodies against low-molecular-weight targets.

Entities:  

Keywords:  Analytical performance; Expression systems; Single-chain variable fragment; Specificity

Mesh:

Substances:

Year:  2017        PMID: 29027080     DOI: 10.1007/s11418-017-1136-z

Source DB:  PubMed          Journal:  J Nat Med        ISSN: 1340-3443            Impact factor:   2.343


  19 in total

1.  Expression and purification of a novel therapeutic single-chain variable fragment antibody against BNP from inclusion bodies of Escherichia coli.

Authors:  Dawei Bu; Yuwei Zhou; Jian Tang; Fang Jing; Wei Zhang
Journal:  Protein Expr Purif       Date:  2013-10-12       Impact factor: 1.650

2.  One-step detection of aflatoxin-B(1) using scFv-alkaline phosphatase-fusion selected from human phage display antibody library.

Authors:  Kuntalee Rangnoi; Nanthnit Jaruseranee; Richard O'Kennedy; Potjamas Pansri; Montarop Yamabhai
Journal:  Mol Biotechnol       Date:  2011-11       Impact factor: 2.695

3.  Anti-digoxin scFv fragments expressed in bacteria and in insect cells have different antigen binding properties.

Authors:  C Lemeulle; T Chardès; C Montavon; H Chaabihi; J C Mani; M Pugnière; M Cerutti; G Devauchelle; B Pau; M Biard-Piechaczyk
Journal:  FEBS Lett       Date:  1998-02-20       Impact factor: 4.124

4.  Use of single chain antibody derivatives for targeted drug delivery.

Authors:  Yaghoub Safdari; Vahideh Ahmadzadeh; Masoumeh Khalili; Hossein Zarei Jaliani; Vahid Zarei; Vahid Erfani-Moghadam
Journal:  Mol Med       Date:  2016-04-22       Impact factor: 6.354

5.  Protective and therapeutic capacity of human single-chain Fv-Fc fusion proteins against West Nile virus.

Authors:  L Hannah Gould; Jianhua Sui; Harald Foellmer; Theodore Oliphant; Tian Wang; Michel Ledizet; Akikazu Murakami; Kristin Noonan; Cassandra Lambeth; Kalipada Kar; John F Anderson; Aravinda M de Silva; Michael S Diamond; Raymond A Koski; Wayne A Marasco; Erol Fikrig
Journal:  J Virol       Date:  2005-12       Impact factor: 5.103

6.  Production and validation of the pharmacokinetics of a single-chain Fv fragment of the MGR6 antibody for targeting of tumors expressing HER-2.

Authors:  F Turatti; D Mezzanzanica; E Nardini; E Luison; L Maffioli; E Bambardieri; C de Lalla; S Canevari; M Figini
Journal:  Cancer Immunol Immunother       Date:  2001-02       Impact factor: 6.968

7.  Development of an indirect competitive enzyme-linked immunosorbent assay (icELISA) using highly specific monoclonal antibody against paclitaxel.

Authors:  Zhi Chao; Mingming Tan; Madan Kumar Paudel; Seiichi Sakamoto; Liling Ma; Kaori Sasaki-Tabata; Hiroyuki Tanaka; Yukihiro Shoyama; Lijiang Xuan; Satoshi Morimoto
Journal:  J Nat Med       Date:  2012-09-25       Impact factor: 2.343

8.  Efficient expression of single chain variable fragment antibody against paclitaxel using the Bombyx mori nucleopolyhedrovirus bacmid DNA system and its characterizations.

Authors:  Gorawit Yusakul; Seiichi Sakamoto; Hiroyuki Tanaka; Satoshi Morimoto
Journal:  J Nat Med       Date:  2016-03-03       Impact factor: 2.343

9.  Efficient serum clearance of botulinum neurotoxin achieved using a pool of small antitoxin binding agents.

Authors:  Jorge Sepulveda; Jean Mukherjee; Saul Tzipori; Lance L Simpson; Charles B Shoemaker
Journal:  Infect Immun       Date:  2009-11-16       Impact factor: 3.441

10.  Construction and expression of specificity-improved single-chain variable fragments against the bioactive naphthoquinone, plumbagin.

Authors:  Seiichi Sakamoto; Futoshi Taura; Waraporn Putalun; Benyakan Pongkitwitoon; Ryota Tsuchihashi; Satoshi Morimoto; Junei Kinjo; Yukihiro Shoyama; Hiroyuki Tanaka
Journal:  Biol Pharm Bull       Date:  2009-03       Impact factor: 2.233

View more
  3 in total

1.  Plant-made antibody against miroestrol: a new platform for expression of full-length immunoglobulin G against small-molecule targets in immunoassays.

Authors:  Kaewta Rattanapisit; Tharita Kitisripanya; Atthaphon Konyanee; Worapol Sae-Foo; Apisit Burapapiruin; Waraporn Putalun; Seiichi Sakamoto; Waranyoo Phoolcharoen; Gorawit Yusakul
Journal:  Plant Cell Rep       Date:  2021-02-13       Impact factor: 4.570

2.  Engineering a single-chain antibody against Trypanosoma cruzi metacyclic trypomastigotes to block cell invasion.

Authors:  Lara Maria Kalempa Demeu; Rodrigo Jahn Soares; Juliana Severo Miranda; Lisandro A Pacheco-Lugo; Kelin Gonçalves Oliveira; Cristian Andrés Cortez Plaza; Philippe Billiald; Juliana Ferreira de Moura; Nobuko Yoshida; Larissa Magalhães Alvarenga; Wanderson Duarte DaRocha
Journal:  PLoS One       Date:  2019-10-16       Impact factor: 3.240

3.  Expression of actively soluble antigen-binding fragment (Fab) antibody and GFP fused Fab in the cytoplasm of the engineered Escherichia coli.

Authors:  Supaluk Krittanai; Waraporn Putalun; Seiichi Sakamoto; Hiroyuki Tanaka; Thaweesak Juengwatanatrakul; Gorawit Yusakul
Journal:  Mol Biol Rep       Date:  2020-05-11       Impact factor: 2.316

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.